Book ChapterDOI
Hyperandrogenism, Polycystic Ovarian Disease
Eugenia Resmini,Mónica González Fernández +1 more
- pp 1-8
Reads0
Chats0
About:
The article was published on 2013-01-01. It has received 0 citations till now. The article focuses on the topics: Polycystic ovarian disease & Hyperandrogenism.read more
References
More filters
Journal ArticleDOI
Rosiglitazone and cardiovascular risk.
Bruce M. Psaty,Curt D. Furberg +1 more
TL;DR: A meta-analysis of treatment trials of rosiglitazone, as compared either with other therapies for type 2 diabetes or with placebo, finds no significant differences between the two treatments.
Journal ArticleDOI
Neuroendocrine dysfunction in polycystic ovary syndrome
Christine M. Burt Solorzano,Jennifer P. Beller,Michelle Y. Abshire,Jessicah S. Collins,Christopher R. McCartney,John C. Marshall +5 more
TL;DR: HA may adversely affect LH pulse regulation during pubertal maturation leading to persistent HA and the development of PCOS, potentially related to normally increasing levels of testosterone during puberty.
Journal ArticleDOI
Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome
Renato Pasquali,Francesco Casimirri,Stefano Venturoli,Maria Antonio,Labate Morselli,Sandro Reho,Anna Pezzoli,Roberto Paradisi +7 more
TL;DR: As WHR values increased, a significantly greater prevalence of obesity and acanthosis nigricans and a lower prevalence of acne was present in the PCOS group, and no significant differences were present in any of the other clinical features between the three groups.
Journal ArticleDOI
Mechanism of action of metformin: insulin receptor and postreceptor effects in vitro and in vivo.
Fantus Ig,Brosseau R +1 more
TL;DR: Met has an acute insulin-like effect in vitro independent of its ability to increase insulin binding and in vivo in patients with poorly controlled NIDDM, and acts in vivo predominantly at a postreceptor site to lower plasma glucose.
Journal ArticleDOI
The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women.
TL;DR: Obesity, but neither hyperandrogenaemia nor hyperinsulinaemia, was associated with significant decreases in HDL levels and was therefore the major factor affecting lipid profiles in PCO; a significant relationship existed between androgen and lipoprotein levels only in nob PCO women, suggesting that the mechanisms underlying these associations are complex.